A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
NCT02609230
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Advanced Solid Tumors
Multiple Myeloma
Interventions
DRUG:
ONC-201
Sponsor
Fox Chase Cancer Center